Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Taxane · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Taxane (Cytotoxic, BAY59-8862) | DRUG | Daily 1 h infusion every 3 weeks |
Inclusion Criteria: - Measurable disease as defined by the presence of at least one measurable lesion - Failed at least one prior therapy or has achieved remission but has progressed or relapsed within 6 months of therapy - Life expectancy of at least 12 weeks - Adequate bone marrow, liver and kidne...
Taxane is an investigational small molecule being studied for the treatment of lymphoma, specifically aggressive, refractory non-Hodgkin's lymphoma. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Taxane is being developed by Bayer AG, a pharmaceutical company traded on the OTC market under the ticker symbol BAYRY. The drug is currently in Phase 2 clinical trials for non-Hodgkin's lymphoma.
Taxane is in Phase 2 clinical development. It has completed one Phase 2 trial for aggressive, refractory non-Hodgkin's lymphoma, and the drug remains investigational, meaning it is not yet approved for commercial use.
Taxane has been studied in one completed Phase 2 clinical trial, identified as NCT00044551, titled 'Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma.' The trial enrolled 29 participants across the United States, Canada, France, Germany, Netherlands, and the United Kingdom.
Yes, Taxane is also known as Bay 59-8862. In clinical trial NCT00044551, the drug is referred to as Bay 59-8862, and it was evaluated in patients with aggressive, refractory non-Hodgkin's lymphoma.